论文部分内容阅读
抑制物是一种可中和凝血因子活性的抗体。当血友病A或血友病B患者输入了外源性因子Ⅷ或Ⅸ时,便可引起抗因子Ⅷ、抗因子Ⅸ的同种抗体产生。在非血友病的病人亦可能会产生因子Ⅷ抑制物的自身抗体,但此处不作讨论。1发生率及流行病学在一定的时间内,人群中新抑制物的数量可反映出是暂时抑制物抑或是长期抑制物。随着试验次数的增多,可发现更多的暂时性抑制物,其抑制物的发生率也明显增高。在一定时间内(流行病学)人群中存在抗体抑制物的数量主要反映长期抑制物。严重血友病A患者在患病初期因子Ⅷ抑制物发生率的范围为10%～50%(通常20%～30%)。流行病学较低,为10%～20%。在严重的血友病B中,其抑制物的流行病学约为4%。
Inhibitors are antibodies that neutralize the activity of clotting factors. When exogenous factor VIII or IX is introduced into hemophilia A or hemophilia B, alloantibodies against factor VIII and anti-factor IX can be induced. Autoantibodies to factor VIII inhibitors may also be produced in patients with non-haemophilia but are not discussed here. 1 incidence and epidemiology in a certain period of time, the population of new inhibitors may reflect the number of temporary inhibitors or long-term inhibitors. As the number of tests increased, more transient inhibitors could be found, and their incidence of inhibitors was also significantly increased. The amount of antibody inhibitors present in the population (epidemiological) over time reflects mainly long-term inhibitors. Severe hemophilia A patients in the early stages of factor Ⅷ inhibitor incidence range of 10% to 50% (usually 20% to 30%). Epidemiology is low, 10% to 20%. In severe hemophilia B, the epidemiology of its inhibitor is about 4%.